Cargando…
Eptifibatide and abciximab inhibit insulin-induced focal adhesion formation and proliferative responses in human aortic smooth muscle cells
BACKGROUND: The use of abciximab (c7E3 Fab) or eptifibatide improves clinical outcomes in diabetics undergoing percutaneous coronary intervention. These β(3 )integrin inhibitors antagonize fibrinogen binding to α(IIb)β(3 )integrins on platelets and ligand binding to α(v)β(3 )integrins on vascular ce...
Autores principales: | Pathak, Alokkumar, Zhao, Renyi, Huang, Jianhua, Stouffer, George A |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2628888/ https://www.ncbi.nlm.nih.gov/pubmed/19108709 http://dx.doi.org/10.1186/1475-2840-7-36 |
Ejemplares similares
-
Early recovery of microvascular perfusion induced by t-PA in combination with abciximab or eptifibatide during postischemic reperfusion
por: Bertuglia, Silva, et al.
Publicado: (2002) -
Comparison between Intracoronary Abciximab and Intravenous Eptifibatide Administration during Primary Percutaneous Coronary Intervention of Acute ST-Segment Elevation Myocardial Infarction
por: Namazi, Mohammad Hasan, et al.
Publicado: (2013) -
Effects of Restoration of Blood Flow on the Development of Aortic Atherosclerosis in ApoE(−/−) Mice With Unilateral Renal Artery Stenosis
por: Pathak, Alokkumar S., et al.
Publicado: (2016) -
Abciximab: Abciximab-induced alveolar haemorrhage: case report
Publicado: (2021) -
Expression of Cyr61 in ApoE(−/−) mice with chronic unilateral renal artery ligation
por: Pathak, Alokkumar S., et al.
Publicado: (2021)